Standing on the cusp of something great: How real-world data is poised to transform cancer careREAL-WORLD EVIDENCE IN ONCOLOGY: Towards Innovative and Affordable Patient Care How can real world evidence (RWE) improve the Share XStanding on the cusp of something great: How real-world data is poised to transform cancer carehttps://pharmaphorum.com/whitepapers/standing-cusp-something-great-real-world-data-poised-transform-cancer-care/
CAR-Ts dominated the agenda at ASH 2017The American Society for Hematology congress was dominated by CAR-T therapies – their potential new uses, how to Share XCAR-Ts dominated the agenda at ASH 2017https://pharmaphorum.com/views-analysis-oncology/car-ts-dominated-agenda-ash-2017/
ASH 2017: CAR-T therapy and beyondAs the American Society of Hematology’s 2017 congress approaches, there’s plenty to be excited about – not just Share XASH 2017: CAR-T therapy and beyondhttps://pharmaphorum.com/views-analysis-oncology/ash-2017-car-t-therapy-beyond/
Biosimilars in oncology: a €2billion opportunity for European healthcareIQVIA’s Murray Aitken examines the potential for savings from a new wave of oncology biosimilars – but says Share XBiosimilars in oncology: a €2billion opportunity for European healthcarehttps://pharmaphorum.com/views-and-analysis/biosimilars-oncology-european-healthcare/
Innovations in cancer drug researchWhile cancer continues to be one of the leading causes of death and illness, new technology and increasing Share XInnovations in cancer drug researchhttps://pharmaphorum.com/views-and-analysis/innovations-cancer-drug-research/
